Background Sirolimus-eluting stents (SES) reduce restenosis and revascularization rates, compared with baremetal stents (BMS), in elective percutaneous coronary intervention (PCI). This study investigated the safety and efficacy of SES for emergency PCI in acute coronary syndrome (ACS) patients.
he pathological condition of acute coronary syndrome (ACS) is rupture of plaque, followed by the formation of thrombosis because of partial or complete occlusion of the coronary artery. The purpose of percutaneous coronary intervention (PCI) in ACS patients is to decrease cardiovascular events by recanalizing the culprit coronary artery at the earliest stage.
The sirolimus-eluting stent (SES; Cypher ® , Johnson & Johnson, New Brunswick, NJ, USA) has been shown to reduce restenosis and revascularization rates, compared with bare-metal stents (BMS), in elective PCI. [1] [2] [3] [4] [5] On the other hand, the efficacy of primary stenting using BMS in ACS patients has been previously demonstrated. [6] [7] [8] [9] Delayed endothelialization of these stents raises concern about a possible increase in the incidence of stent thrombosis. In the recently reported TYPHOON 10 and PASSION 11 trials, the use of drug-eluting stents in cases of acute myocardial infarction (AMI) reduced the incidence of cardiac events. However, the safety and efficacy of SES in ACS patients have not been investigated in Japan.
Methods

Patients
We enrolled 154 consecutive patients (SES: n=77, BMS: n=77) admitted to hospital with ACS between January 2005 and July 2006. This study was a retrospective and nonrandomized study. All patients underwent emergency PCI while admitted to the coronary care unit (CCU). Written informed consent was given by all patients.
ACS consisted of unstable angina pectoris, I-III B according to Braunwald's classification, 12 and AMI. AMI was defined as typical chest pain, electrocardiographic changes and creatine kinase elevation to twice the upper limit of normal.
Procedure
While in the CCU, all patients received 3,000-5,000 units of heparin, as well as oral doses of aspirin 200 mg, ticlopidine 200 mg, and cilostazol 200 mg before primary PCI was performed by the transfemoral approach in all cases. After passing a guidewire, a thrombectomy device was used when possible, prior to expanding the balloon. The operator decided whether to use a SES or BMS and procedural success was defined as whether the stent could be placed at the target site, the residual stenosis was <50%, and final imaging showed that Thrombolysis In Myocardial Infarction 3 recanalization had been attained. group. All patients received oral aspirin 100 mg/day for an unlimited period. Clinical follow-up, based on the patients' charts, was performed 30 days and 8 months after the PCI procedure. Restenosis was assessed by myocardial scintigraphy in most patients. Follow-up coronary angiography (CAG) was performed for those patients with findings of ischemia. Patients considered ineligible for assessment of ischemia by myocardial scintigraphy, following multivessel stent placement, were assessed for restenosis by CAG. Repeat PCI was performed for those patients found to have ≥75% stenosis and findings of ischemia on myocardial scintigraphy.
Events
Major adverse cardiac events (MACE) were defined as cardiac death, recurrence of myocardial infarction (MI), and target lesion revascularization (TLR), which was defined as repeat PCI or bypass grafting of the target vessel. Stent thrombosis was defined as confirmation by CAG.
Statistical Analysis
Baseline data are shown as percentage or mean ± SD.
Two groups of metric variables were compared using t-test, and nonparametric variables were compared by the MannWhitney U test. A p-value below 0.05 was statistically significant. The cumulative incidence of cardiovascular events 8 months after PCI was investigated by Kaplan-Meier. StatView 5.0 software (Abacus Concepts, Calabasus, CA, USA) was used for the analyses.
Results
There were no differences between the 2 groups regarding age and sex, or for coronary risk factors such as hypertension, hyperlipidemia, diabetes, and smoking status (Table 1) . However, there were more AMI patients in the BMS group (SES vs BMS: 59.7% vs 88.3%; p<0.0001).
On angiography, with regard to the culprit lesion, the right coronary artery (RCA) was prevalent in the BMS group (13.0% vs 50.6%; p<0.0001) whereas the left anterior descending artery was prevalent in the SES group (68.3% vs 28.6%; p<0.0001). As for the number of lesions, 1-vessel disease was prevalent in the SES group (64.9% vs 46.8%; p<0.02), whereas 2-vessel disease was prevalent in the Table 3 Postoperative Results Table 1 .
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BMS group (26.0% vs 41.6%; p<0.04). There was no difference between the 2 groups for 3-vessel disease (Table 2) or for infarct size, reflected by the peak creatine kinase and troponin T concentrations. There was no difference between the 2 groups regarding the rates of procedural success and delivery success; moreover, implantation of the Cypher ® stent was successful in all the patients. In the BMS group, the stent became undeliverable in 1 patient because of a highly calcified and tortuous RCA and as the patient had 3-vessel disease, CABG was performed.
Reference vessel diameter and length of lesion did not differ between the 2 groups. However, the diameter of stent used in the BMS group was significantly larger (3.04± 0.05 mm vs 3.24±0.06 mm; p=0.01), the stent length was significantly greater in the SES group (25.7±1.4 mm vs 21.2±1.0 mm; p=0.01), but the number of stents per patient did not differ between the 2 groups (Table 3) .
After 30 days, there was no difference between the groups regarding cardiac death, recurrence of MI, repeat PCI and MACE (Fig 1) . After 8 months, there was no difference between the groups regarding the incidence of cardiac death and recurrence of MI, but patients treated with SES had lower rates of repeat PCI (5.6% vs 18.6%; p=0.04) and MACE (9.7% vs 27.1%; p=0.01). Stent thrombosis occurred in 1 and 2 patients in the SES and BMS groups, respectively, but there was no statistical difference between the 2 groups (1.4% vs 2.9%; p=0.59) (Figs 2,3) .
The period of ticlopidine treatment was 183±12 days in the SES group and 95±17 days in the BMS group (p< 0.0001). There was no difference between the 2 groups regarding discontinuation of treatment because of adverse reactions (11.1% vs 7.1%; p=0.51). Most of the adverse reactions were related to liver dysfunction, with thrombocytopenia occurring in 1 patient, but none was life-threatening. There was no patient in either group who discontinued treatment because of stent thrombosis (Table 4) .
Discussion
The Cypher stent has a layer of the immunosuppressant drug, sirolimus, on the surface, which prevents restenosis by inhibiting neointimal proliferation. The rate of restenosis with the SES is reported to be 2.3-8.9% and with TLR it is 4.1-6%. [1] [2] [3] [4] In the present study, use of SES in ACS patients significantly reduced the rate of cardiovascular events after 8 months (9.7% vs 27.1%; p=0.01), because SES decreases the incidence of restenosis, which significantly reduces the rate of repeat PCI (5.6% vs 24.3%; p=0.006). In the recently reported TYPHOON trial, which compared treatment of acute MI using a Cypher stent vs BMS, there was no difference in the incidence of early thrombosis and there was also no difference in stent thrombosis at 1 year (3.4% vs 3.6%). In addition, TLR was significantly lower in patients with the Cypher stent (7.3% vs 14.3%) at 1 year, showing that the stent is effective in patients with AMI. 10 In elective cases, the incidence of stent thrombosis with DES is reportedly 0-1.1%. [13] [14] [15] [16] In the PASSION trial of treatment with paclitaxel-eluting stents in patients with AMI, the incidence of stent thrombosis was as low as 1%. 11 In the STRATEGY trial, the incidence of stent thrombosis was 0% in the group receiving SES and 3% in group receiving BMS. 17 When DES are used in cases of ACS, which is a thrombotic lesion, the risk of early thrombosis is thought to increase, but in the present study, there was no thrombosis up to 30 days after implantation of the Cypher stent. Late thrombosis after 8 months occurred in 1 patient in the SES group and 2 in the BMS group, showing no significant difference (1.4% vs 2.9%; p=0.59), and was equivalent to the incidence reported to date for elective PCI. By using SES in ACS patients, the rate of cardiovascular events was lowered with no increase in the incidence of stent thrombosis.
When using the Cypher stent for emergency PCI, administering ticlopidine without confirming its tolerability will be a problem. It is mandatory for patients with Cypher stent placement to be given ticlopidine for at least 3 months. Takeyasu et al reported the onset of adverse reactions after PCI because of ticlopidine to be 7% 18 and Fukushima et al reported it to be 9.3%. 19 In the present study, ticlopidine was administered for a mean of approximately 6 months after implantation of the Cypher stent and was discontinued in 11.1% of the patients because of adverse reactions. There were no cases of stent thrombosis related to discontinuation of ticlopidine, so even in terms of safety, the treatment was considered to be tolerable.
There were more patients in the BMS group with RCA culprit lesions, but because this was a retrospective study, the operator decided which stent to choose. The RCA has a large vessel diameter and there are many cases of tortuous lesions, so BMS may have been commonly selected. The size of the Cypher stent ranges from 2.5 mm to 3.5 mm, so it is necessary to use BMS when the vessel diameter is 3.5 mm or more, which is probably why BMS are commonly used in the RCA. In the present study, BMS were commonly used in RCA, so there was no effect on the rates of restenosis and TLR.
Small vessels and diffuse stenotic lesions have been identified as causal factors of restenosis after PCI. The Cypher stent that was used in this study has a long length and small diameter compared with BMS, but the rate of revascularization was significantly lower. In elective PCI, it is recommended that the Cypher stent be placed such that it matches the diameter of the blood vessel and fully covers the lesion 20 and, as the present results show, similarly placing the Cypher stent in emergency PCI will generally prevent restenosis.
Recently, very late stent thrombosis occurring from 1 year onwards after DES implantation has become a problem. The incidence in ACS is unknown, and hereafter follow-up examinations and progress observations are necessary because there are no reports on the long-term results of SES in ACS. Even in this study, future follow-up examinations and progress observation are necessary.
Study Limitation
Stent selection was left to the operator's discretion, because it was a non-randomized study, and therefore lesion characteristics may differ between the groups.
Conclusion
In emergency PCI for ACS patients, the SES significantly reduced cardiovascular events by decreasing the need for repeat PCI, compared with BMS. The safety profile of both types of stent is equivalent, with no increase in stent thrombosis.
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